Christopher P. Leamon

7.9k citations

94 papers · 6.6k indexed · 2 hit papers · h-index 43

Impact in

Biomaterials top 0.5%
- Nanoparticle-Based Drug Delivery
Oncology top 1%
- Peptidase Inhibition and Analysis

Papers in

Oncology 39
- Cancer-related Molecular Pathways 10
- Cancer Treatment and Pharmacology 10
- Peptidase Inhibition and Analysis 8
Biotechnology 11
- Cancer Research and Treatments 7

Co-authors: Philip S. Low Joseph A. Reddy Iontcho R. Vlahov Elaine Westrick Nikki Parker Mary Jo Turk Jeffrey D. Lewis Marilynn Vetzel
Journals: Cancer Research (15 papers)Bioconjugate Chemistry (10 papers)Bioorganic & Medicinal Chemistry Letters (6 papers)Molecular Pharmaceutics (6 papers)Molecular Cancer Therapeutics (3 papers)
Partner nations: United States Switzerland United Kingdom

In The Last Decade

Christopher P. Leamon

94 papers receiving 6.5k citations

Hit Papers

align trajectories log scale

The folate receptor as a rational therapeutic target for personalized cancer treatment 2014 · 329 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2014 Drug Resistance Updates
2005 Analytical Biochemistry

Peers

Countries citing papers authored by Christopher P. Leamon

Since Specialization

Citations

This map shows the geographic impact of Christopher P. Leamon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher P. Leamon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher P. Leamon more than expected).

Fields of papers citing papers by Christopher P. Leamon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher P. Leamon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher P. Leamon. The network helps show where Christopher P. Leamon may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Christopher P. Leamon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Christopher P. Leamon Line = papers co-authored together Christopher P. Leamon links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Targeting folate receptor beta on monocytes/macrophages renders rapid inflammation resolution independent of root causes Cell Reports Medicine ·Yingjuan Lu, Leroy W. Wheeler, Haiyan Chu, Paul J. Kleindl, Michael Pugh, Fei You, 武生後藤, Gabriela García, Henry Yim Wu, Andre Pires da Cunha, Richard J. Johnson, Elaine Westrick, Kazue Mineo, Fansiska Xaveria Lau, Ahmad Wari, Patrick Klein, Iontcho R. Vlahov, Philip S. Low, Christopher P. Leamon	2021	13
2	Design and synthesis of a folate-receptor targeted diazepine-ring-opened pyrrolobenzodiazepine prodrug conjugate Bioorganic & Medicinal Chemistry Letters ·Iontcho R. Vlahov, Sagrario Concepción Vela Velez, Hari Krishna R. Santhapuram, M.D. Chavez Clemente, Georg Ernst, Ning Zou, Kevin Wang, Fei You, 王章涛 Wang Zhangtao, 西拉里·M·西茨, Hanna F. Klein, Paul J. Kleindl, Jen Slaughter, Nohra Shwan Hanna, Daza Laguna A, Christopher P. Leamon	2020	7
3	Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters Nature Communications ·Yong Gu Lee, Haiyan Chu, Yingjuan Lu, Christopher P. Leamon, Madduri Srinivasarao, Karson S. Putt, Philip S. Low	2019	82
4	Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis Toxicology and Applied Pharmacology ·April D. Lake, Rhiannon N. Hardwick, Christopher P. Leamon, Philip S. Low, Nathan J. Cherrington	2019	4
5	Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy Cancer Chemotherapy and Pharmacology ·Christopher P. Leamon, Joseph A. Reddy, Iontcho R. Vlahov, Ryan Dorton, Lilian Mara Torquete da Silva, Marilynn Vetzel, Patrick Klein, Elaine Westrick, Le-Cun Xu, Yu Wang	2017	10
6	High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide Molecular Cancer Therapeutics ·Amy D. Guertin, Jennifer O’Neil, Alexander Stoeck, Joseph A. Reddy, Răzvan Cristescu, Brian B. Haines, Турушев Николай Иванович, Ryan Dorton, Lilian Mara Torquete da Silva, Melissa Nelson, Marilynn Vetzel, Serguei Lejnine, Michael Nebozhyn, Theresa Zhang, Andrey Loboda, Bruno Watanabe [UNESP] Minto, Emmett V. Schmidt, Isabelle Dussault, Christopher P. Leamon	2016	16
7	Development and validation of a UPLC–MS/MS method for the novel folate-targeted small molecule drug conjugate EC1456 and its metabolites in tumor homogenates from mice Journal of Pharmaceutical and Biomedical Analysis ·巧伊原, Michael Pugh, Melissa Nelson, Joseph A. Reddy, Patrick Klein, Christopher P. Leamon	2016	4
8	Antiinflammatory Activity of a Novel Folic Acid Targeted Conjugate of the mTOR Inhibitor Everolimus Molecular Medicine ·Yingjuan Lu, Nikki Parker, Paul J. Kleindl, Kazue Mineo, L E Park, Elaine Westrick, Emilia Alfonsea Sáez, Martin Felsen, Kevin Wang, Hari Krishna R. Santhapuram, Fei You, 西拉里·M·西茨, 王章涛 Wang Zhangtao, Patrick Klein, Iontcho R. Vlahov, Philip S. Low, Christopher P. Leamon	2015	21
9	PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer Journal of Clinical Oncology ·R. Wendel Naumann, Robert L. Coleman, Robert A. Burger, Edward A. Sausville, E. Kutarska, Sharad Ghamande, Nashat Gabrail, Stephen DePasquale, Elżbieta Nowara, Lucy Gilbert, Robert H. Gersh, Michael Teneriello, Wael A. Harb, Panagiotis A. Konstantinopoulos, Richard T. Penson, James T. Symanowski, Kyung Hoon Lim, Christopher P. Leamon, David Morgenstern, Richard A. Messmann	2013	169
10	177Lu-EC0800 Combined with the Antifolate Pemetrexed: Preclinical Pilot Study of Folate Receptor Targeted Radionuclide Tumor Therapy Molecular Cancer Therapeutics ·Josefine Reber, Stephanie Haller, Christopher P. Leamon, Cristina Müller	2013	18
11	Expression of functional folate receptors by human parathyroid cells Surgery ·Collin J. Weber, Susan Müller, Susan A. Safley, K Ishibashi, Praveen K. Amancha, François Villinger, Vernon M. Camp, Małgorzata Lipowska, Jyotirmay Sharma, Cristina Müller, Roger Schibli, Philip S. Low, Christopher P. Leamon, Raghuveer Halkar	2013	7
12	Engineering Folate–Drug Conjugates to Target Cancer: From Chemistry to Clinic Bioconjugate Chemistry ·Iontcho R. Vlahov, Christopher P. Leamon	2012	206
13	Design and regioselective synthesis of a new generation of targeted therapeutics. Part 3: Folate conjugates of aminopterin hydrazide for the treatment of inflammation Bioorganic & Medicinal Chemistry Letters ·Iontcho R. Vlahov, Fei You, Hari Krishna R. Santhapuram, 水梦仙, 王章涛 Wang Zhangtao, 西拉里·M·西茨, Paul J. Kleindl, Mingjin Fan, Christopher P. Leamon	2010	15
14	Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid Bioorganic & Medicinal Chemistry Letters ·Iontcho R. Vlahov, Gregory D. Vite, Paul J. Kleindl, Yu Wang, Hari Krishna R. Santhapuram, Fei You, Stephen Howard, Soong‐Hoon Kim, Bai Feng, Christopher P. Leamon	2010	29
15	Properties Influencing the Relative Binding Affinity of Pteroate Derivatives and Drug Conjugates Thereof to the Folate Receptor Pharmaceutical Research ·Christopher P. Leamon, Fei You, Hari Krishna R. Santhapuram, Mingjin Fan, Iontcho R. Vlahov	2009	28
16	Synthesis and in vitro effects of BMS-753493, an epothilone-folate conjugate designed to selectively target FR expressing tumor cells Cancer Research ·Gregory D. Vite, Iontcho R. Vlahov, Steven Howard, Soong‐Hoon Kim, Paul J. Kleindl, Hari Krishna R. Santhapuram, Yu Wang, Mei-Li Wen, Christopher P. Leamon, Francis Lee	2008	2
17	Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates Journal of Pharmacology and Experimental Therapeutics ·Christopher P. Leamon, Joseph A. Reddy, Ryan Dorton, Lilian Mara Torquete da Silva, C.L. Segaser, Nikki Parker, Elaine Westrick	2008	56
18	Folate receptor targeted anti-tumor activity of EC-0225, a folate-targeted dual drug conjugate Cancer Research ·Joseph A. Reddy, Hari Krishna R. Santhapuram, Elaine Westrick, Marilynn Vetzel, L.G. Solbé, Ryan Dorton, Ye Kyeong Shin, Iontcho R. Vlahov, Christopher P. Leamon	2006	1
19	Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide Bioorganic & Medicinal Chemistry Letters ·Iontcho R. Vlahov, Hari Krishna R. Santhapuram, Paul J. Kleindl, Stephen Howard, ویلیام آر استنک, Christopher P. Leamon	2006	107
20	Selective Targeting of Malignant Cells with Cytotoxin-Folate Conjugates Journal of drug targeting ·Christopher P. Leamon, Philip S. Low	1994	82

About Christopher P. Leamon

Christopher P. Leamon is a scholar working on Oncology, Biotechnology, Rheumatology, Physiology and Organic Chemistry, having authored 94 papers that have together received 6.6k indexed citations. Recurring topics across this work include Folate and B Vitamins Research (17 papers), Click Chemistry and Applications (12 papers), Radiopharmaceutical Chemistry and Applications (12 papers), Cancer-related Molecular Pathways (10 papers), Cancer Treatment and Pharmacology (10 papers), Peptidase Inhibition and Analysis (8 papers), RNA Interference and Gene Delivery (7 papers) and Cancer Research and Treatments (7 papers). The work is most often cited by research in Biomaterials (1.7k citations), Oncology (1.7k citations), Radiology, Nuclear Medicine and Imaging (1.1k citations), Molecular Biology (3.2k citations) and Rheumatology (661 citations). Christopher P. Leamon has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Philip S. Low, Joseph A. Reddy, Iontcho R. Vlahov, Elaine Westrick, Nikki Parker, Mary Jo Turk, Jeffrey D. Lewis, Marilynn Vetzel, Yehuda G. Assaraf and Paul J. Kleindl. Their work appears in journals such as Cancer Research, Bioconjugate Chemistry, Bioorganic & Medicinal Chemistry Letters, Molecular Pharmaceutics and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact